
    
      Patients will be recruited over 2 years. They must have a histologically proven diagnosis of
      mantle cell lymphoma, be aged from 18 to 65 years at the time of registration. Patients must
      be eligible for autologous transplant and not previously treated for their lymphoma at
      inclusion. Patients will receive 4 cycles of Obinutuzumab (GA101) and
      Cisplatinum-Cytarabine-Dexamethasone (GA-DHAP) every 21 days followed by Autologous Stem Cell
      Transplant (ASCT) using a GA101-Carmustine- Etoposide- Cytarabine- Melphalan (GA-BEAM)
      conditioning regimen plus a Obinutuzumab maintenance for 3 years then a Obinutuzumab
      maintenance on demand according to MRD status. Stem cells will be collected after cycle 3
      and/or 4 of GA-DHAP.
    
  